AmgenFRA:AMG +0.27%87 Days Payable is 87.66 as of Mar. 2026, which is 6% above its 10-year median of 82.63. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €307.90 (Fairly Valued). The stock has 8 warning signs investors should review. Among 920 Drug Manufacturers companies, Amgen ranks worse than 54.24% on this metric.
Amgen's average Accounts Payable for the
three
months ended in Mar. 2026 was €2,280 Mil. Amgen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2,374 Mil.
Hence, Amgen's Days Payable for the
three
months ended in Mar. 2026 was 87.66.
The historical rank and industry rank for Amgen's Days Payable or its related term are showing as below:
FRA:AMG'
s Days Payable Range Over the Past 10 Years
Min: 49.65 Med: 82.63 Max: 113.88
Current: 83.77
During the past 13 years, Amgen's highest Days Payable was 113.88. The lowest was 49.65. And the median was 82.63.
FRA:AMG's Days Payable is ranked worse than 54.24% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:AMG: 83.77
Amgen's Days Payable
increased
from Mar. 2025 (67.27) to Mar. 2026 (87.66).
It may suggest that Amgendelayed paying its suppliers.
Amgen Days Payable Related Terms
Amgen Days Payable Historical Data
* Premium members only.
The historical data trend for Amgen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AMG vs GILD, PFE, BMY: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Amgen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Days Payable distribution charts can be found below:
* The bar in red indicates where Amgen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Amgen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (FRA:AMG) has a Days Payable of 87.66 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amgen and its competitors. This is near median its historical median of 82.63. Over the past decade, Amgen's Days Payable has ranged from 49.65 to 113.88. According to the industry distribution chart, Amgen ranks #499 out of 920 companies in the Drug Manufacturers industry, placing it in the top 54.2%.
Is Amgen's Days Payable too high?
Amgen's current Days Payable of 87.66 is near median its 10-year median of 82.63. Over the past 10 years, this metric has ranged from a low of 49.65 to a high of 113.88. The Drug Manufacturers industry median Days Payable is 90.84. Amgen's value of 87.66 is 3.5% below this industry median. Based on the distribution chart, Amgen ranks #499 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Days Payable compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #499 out of 920 companies for Days Payable. This places Amgen in the lower half of its industry. The industry median Days Payable is 90.84. Amgen's value of 87.66 is 3.5% below this benchmark. Historically, Amgen's own Days Payable has ranged from 49.65 to 113.88 over the past decade. While the company's 10-year median is 82.63 vs. the industry median of 90.84, Amgen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Days Payable of 87.66 is 3.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Days Payable is 87.66, which is near median its own 10-year median of 82.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €307.90, compared to a current price of €314.00 — trading 2% above its estimated fair value. The current Days Payable is 87.66, which is near median its 10-year median of 82.63 and 3.5% below the Drug Manufacturers industry median of 90.84. Amgen's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Days Payable is 87.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (FRA:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €314.00 is trading 2% above its estimated GF Value™ of €307.90.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for FRA:AMG:
Days Payable: 87.66 (near median its 10-year median of 82.63)
GF Value™: €307.90 vs. price of €314.00 (2% above fair value)
Industry Position: 3.5% below the Drug Manufacturers median (#499 of 920)
No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for FRA:AMG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AMG has been successfully added to your 
